Psyence Biomedical draws attention premarket after filing on 30% stake
Psyence Biomedical shares rose to $3.95 in premarket trading after a Schedule 13D filing showed Psyence Labs Ltd. holds 30.05% of shares with full voting power. Psyence Labs may buy, sell, or hedge its stake. The company recently began dosing in a Phase IIb trial of NPX-5 psilocybin for cancer-related adjustment disorder. Psyence emphasizes control over its supply chain and GMP manufacturing for regulated psychedelics.